OA
ANIK icon

OFI Advisors’s Anika Therapeutics ANIK Stock Holding History

OFI Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$40K Sell
1,265
-209
-14% -$7.29K ﹤0.01% 1604
2015
Q2 		$49K Buy
1,474
+44
+3% +$1.57K ﹤0.01% 1587
2015
Q1 		$59K Buy
1,430
+94
+7% +$3.8K ﹤0.01% 1589
2014
Q4 		$54K Buy
1,336
+234
+21% +$9.15K ﹤0.01% 1593
2014
Q3 		$40K Sell
1,102
-22
-2% -$951 ﹤0.01% 1607
2014
Q2 		$52K Buy
1,124
+223
+25% +$9.92K ﹤0.01% 1587
2014
Q1 		$37K Sell
901
-174
-16% -$6.47K ﹤0.01% 1611
2013
Q4 		$41K Buy
+1,075
New +$33.2K ﹤0.01% 1610

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

OFI Advisors's ANIK Position: Q3 2015 in Review

OFI Advisors reduced its Anika Therapeutics (ANIK) stake by 14% in Q3 2015, selling an estimated $7.29K and leaving 1,265 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

OFI Advisors first reported a position in ANIK in Q4 2013 and has held it in 8 quarters since. The position peaked at $59K in Q1 2015. 138 funds tracked by Wall St. Rank hold ANIK as of Q3 2015.

  • OFI Advisors held 1,265 shares of Anika Therapeutics worth $40K as of Q3 2015.
  • OFI Advisors sold 209 Anika Therapeutics shares in Q3 2015, an estimated $7.29K.
  • Anika Therapeutics made up ﹤0.01% of OFI Advisors's portfolio in Q3 2015, its #1604 holding.
  • OFI Advisors first reported a position in Anika Therapeutics in Q4 2013 and has held it in 8 quarters since.
  • OFI Advisors's Anika Therapeutics position peaked at $59K in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.